Fundraisings and IPOs

Date: 2017-04-04

Type of information: Grant

Company: Novosanis (Belgium)

Investors: Interreg CrossCare (Belgium)

Amount: € 200 000

Funding type: grant

Planned used: The grant allows Novosanis to build a next-generation Colli-Pee™ device optimized for postal delivery in collaboration with living labs Happy Aging (Belgium) and EIZT (the Netherlands). The Colli-Pee™ device is a non-invasive, user-friendly self-sampling device suited for home-based urine collection for online STI testing platforms. In particular, the Colli-Pee™ device allows for standardized collection of the first 20ml of the urine stream, so-called first-void urine in which STIs can be detected, among which Chlamydia trachomatis, Neisseiria gonorrea, Mycoplasma genitalium, and Trichomonas. The project entitled ‘Co-creation of an innovative and user-friendly device optimized for postal delivery and suited for standardized first-void urine collection’ kick-offed April 2017. Co-creation sessions and usability tests by the living labs Happy Ageing and EIZT next to input from postal services and potential customers during the project will optimize human centred design and commercial roll-out.

Others: • On April 4, 2017, Novosanis announced that the company has received a 200kEur grant from Interreg CrossCare.

Therapeutic area: Infectious diseases - Diagnostic

Is general: Yes